Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) - Global Forecast to 2028
[176 Pages Report] The human microbiome market is projected to reach USD 1,598 million by 2028 from USD 894 million in 2025, at a CAGR of 21.3% from 2025 to 2028. Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth.
To know about the assumptions considered for the study, download the pdf brochure
Human Microbiome Market Dynamics
Driver: Increasing focus on human microbiome therapeutics development
Human gut microbiomes play a major role in improving the efficacy of therapeutic compounds. Over the years, studies have shown that the right combination of microbes in the human body is beneficial for treating different conditions. This association between microbes and specific disease states could generate new opportunities for drug developers (or vaccine manufacturers). Microbes are rich sources of enzymes, owing to which they can be used in various therapeutic applications, such as the search for novel therapies.
In the last decade, microbiome therapy has gained widespread importance. During a 10-year timespan (fiscal years 20072016), the National Institutes of Health (NIH) invested USD 215 million on the Human Microbiome Project (HMP) and USD 728 million on extramural human microbiome research activities outside of the HMP over fiscal years 20122016. Similarly, the European Commission established Metagenomics of the Human Intestinal Tract project (MetaHIT), which is mainly focused on gut bacteria. From 2008 to 2012, ~USD 15 million was invested in this project. From 2012 to 2018 ~USD 14 million (EUR 12 million) was invested in MetaCardis (Metagenomics in Cardiometabolic Diseases), which is a major EU-funded research project that investigated the role of gut microbes in cardiometabolic diseases (CMDs). Similarly, Horizon 2020 is one of the biggest EU Research and Innovation programs with funding of nearly USD 96.9 million (80 billion) available over seven years (2014 to 2020).
Many human microbiome-based product companies are awarded funds to accelerate the development of therapeutics drugs. For instance, in 2020, Vedanta Biosciences (US) received funding from the Biomedical Advanced Research and Development Authority (BARDA) of USD 7.4 million, with the potential for an additional USD 69.5 million to advance the clinical development of VE303 for high-risk Clostridioides difficile infection (CDI). Similarly, in 2020, Finch Therapeutics (US) raised USD 90 million in Series D financing from new and existing investors for the development of CP101 through the final stages of clinical development and regulatory submission in Clostridioides difficile infection. The funding will also be used to advance its platform and pipeline, including the initiation of Phase 1b studies evaluating FIN-211 for autism spectrum disorder (ASD) and CP101 for chronic hepatitis B (HBV). Similar funding and investments with a focus on microbiome research for therapeutics development are expected to drive the growth of the human microbiome market in the coming years.
Opportunity: Increasing collaborations between public-private organizations
With several small innovative players operating in the market, there are various high-growth opportunities for key stakeholders to buy out companies so as to study microbiomes in the hope of identifying new drugs and drug targets for various indications, such as obesity, liver disorders, diabetes, and metabolic disorders. Many market leaders are focusing on strategic collaborations and partnerships to increase their product pipelines with well-organized research and development techniques. In the last two years, there have been several collaborations and partnerships involving major companies.
Challenge: Lack of expertise and inadequate research
The concept of bio-ecologic control of the gut has recently been proposed as a novel method of improving human health. This approach involves the use of probiotics and prebiotics. However, the mechanisms by which prebiotic bio-ecologic strategies exert their beneficial health effects remain largely unknown. It is also unknown how bacteria interact with each other or with the human body to cause or prevent certain diseases. Considering the large variability in the human intestinal ecosystem, these approaches are unlikely to fulfill their potential until the exact profile of an individuals microbiome can be determined. Collecting, sequencing, and analyzing DNA from thousands of microbial species living in and on humans requires an interdisciplinary team with the knowledge of clinical ethics, engineering, and bioinformatics.
In June 2019, the US Food and Drug Administration issued a safety alert for fecal transplant procedures after two immune-compromised patients contracted drug-resistant infections. The patients received transplants from the same donor, and one of the patients died. As a result, the agency planned to suspend clinical trials involving the procedure. The FDA is now informing healthcare providers and patients of the potential risk of serious or life-threatening infections with the use of fecal microbiota for transplantation (FMT). Thus, the lack of expertise and inadequacy in detailed research may hinder the growth of the human
microbiome market.
Restraints: Barriers in proving the causal link between dysbiosis and diseases
The human body is home to a diverse community of symbiotic, commensal, and pathogenic microorganisms, collectively known as the microbiota. Various studies also suggested that that only 30-40 species as the bulk of microbiota are shared among individuals. Analyzing specific bacteria from among trillions of species can be a highly challenging task. High-throughput omics technologies can identify the exact bacterial species involved and provide an understanding of how homeostasis between humans and microbes is maintained. According to human microbiome research, dysbiosis of microbiomes results in some of the most chronic and lifestyle diseases, such as obesity, diabetes, and various digestive disorders.
The current approaches for identifying microbial markers for diagnostic purposes need to rely on comparisons with parallel control groups of healthy individuals. Selecting the correct microbial chassis for a microbiota-based therapeutic is challenging, as it is difficult to predict which microbe is best suited for any given application.
While studies suggested that alteration in gut microbiota compositions is associated with disease conditions, but a direct co-relationship remains debatable in humans. The cause-effect relationship of microbiota dysbiosis and diseases rely mainly on data of experimental models, which may not be true for each individual.
The therapeutics segment to account for the largest share of the human microbiome market in 2024
Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The therapeutics segment to account for the largest share of the human microbiome market in 2024. The increase in funding for R&D into microbiome-based therapies worldwide is the major factor driving the growth of this application segment. In addition, technological advancements, the increasing number of clinical trials for the diagnostics segment, and growing collaborations between key market players and research institutes are also supporting market growth.
By disease, the infectious diseases segment is expected to grow at the highest CAGR during the forecast period.
Based on disease, the human microbiome market is segmented into infectious diseases, endocrine & metabolic disorders, gastrointestinal diseases, cancer, and other diseases. The infectious disease segment is expected to register the highest growth rate during the forecast period. Increasing cognizance of the ill-effects of antibiotic use on the natural flora (such as disruptions) has highlighted the need for specific bacterial-targeted therapy for infectious diseases. The rising incidence of infections due to microbial dysbiosis, as a result of antibiotic treatment, and the increasing number of clinical trials for the development of target-specific microbiome-based therapies are the major factors driving the growth of this segment.
By technology, the genomics segment is expected to grow at the highest CAGR during the forecast period.
On the basis of technology, the human microbiome research spending market is segmented into genomics, proteomics, and metabolomics. The genomics segment is expected to register the highest CAGR during the forecast period. The increasing number of projects funded by private and government bodies is a key driver for the genomics market.
North America accounted for the largest share of the human microbiome market .
In 2019, North America accounted for the largest share of the overall market, followed by Europe. Factors such as the increasing incidences of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and the increasing number of microbiome research & clinical activities are responsible for driving the growth of the market in North America
Key Market Players
The major players in the human microbiome market include ENTEROME Bioscience (France), Seres Therapeutics (US) 4D Pharma (UK), Ferring Pharmaceuticals (Switzerland), ViThera Pharmaceuticals (US), Second Genome (US), Vedanta BioSciences (US), and Synlogic (US).
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
Human Microbime Market :20192028 |
|
Base year considered |
Human Microbiome Research Spending Market :2019 |
|
Forecast period |
Human Microbime Market :20252028 |
|
Forecast units |
Values (USD Million) |
|
Segments covered |
Human Microbime MarketProduct, Disease, Application, and Region |
|
Segments covered |
Human Microbiome Research Spending Market Technology |
|
Geographies covered |
Human Microbime Market: North America (US & Canada), Europe, APAC, and RoW |
|
Companies covered |
ENTEROME Bioscience (France), Seres Therapeutics. (US), 4D pharma (UK), Evelo Biosciences (US), OptiBiotix Health (UK), Synlogic (US), Second Genome (US), Vedanta Biosciences (US), Ferring Pharmaceuticals (Switzerland), ViThera Pharmaceuticals (US), BiomX (Israel), DuPont (US), Kaleido (US), YSOPIA Bioscience (France), FlightPath (US), Finch Therapeutics (US), Quantbiome (DBA Thyrve, Inc.) (US), Viome, Inc. (US), DayTwo (US), BIOHM (US), Atlas Biomed (UK), Bione (India), Luxia Scientific (France), Sun Genomics (US), and Metabiomics (US) |
Based on product, the human microbiome market is segmented as follows:
- Probiotics
- Prebiotics
- Diagnostic Tests
- Drugs
- Other Products
Based on disease, the human microbiome market is segmented as follows:
- Infectious Diseases
- Endocrine and Metabolic Disorders
- Gastrointestinal Diseases
- Cancer
- Other Diseases (cardiovascular diseases, neurological disorders, dermatology diseases, immune-modulated disorders, and hematological disorders.
Based on application, the human microbiome market is segmented as follows:
- Therapeutics
- Diagnostics
Based on the technology, the human microbiome research spending market is segmented as follows:
- Genomics
- Sequencing
- 16s rRNA sequencing method
- Whole-genome sequencing method
- Other Sequencing methods (shotgun metagenomic sequencing, transcriptomics, and targeted sequencing.)
- Other Genomic Technologies (Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays)
- Sequencing
- Proteomics
- Metabolomics
Based on region, the human microbiome research spending market is segmented as follows:
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- RoE
- Asia Pacific
- China
- India
- Japan
- RoAPAC
- Rest of the World (RoW)
Recent Developments:
- In 2020, 4D pharma merged with Longevity Acquisition Corporation to gain a NASDAQ listing. In turn, Longevity will support and accelerate the ongoing development of 4D pharmas Live Biotherapeutic. Live Biotherapeutics is a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment, or cure of a disease. .
- In 2020, BiomX collaborated with Boehringer Ingelheim to utilize the microbiome-based biomarker discovery platform to potentially identify biomarkers associated with patient phenotypes in Inflammatory Bowel Disease (IBD).
- In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds
Frequently Asked Questions (FAQ):
Who are the leading players in the human microbiome market?
Some of the leading players in the human microbiome market include ENTEROME Biosceince (France), Seres Therapeutics (US) 4D Pharma (UK), Ferring Pharmaceuticals (Switzerland), ViThera Pharmaceuticals (US), Second Genome (US), Vedanta BioSciences (US), and Synlogic (US).
What are the major drivers and challenges in the human microbiome market?
Market growth is largely driven by the increasing focus on the development of human microbiome therapy. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth
What are the major product segments in the human microbiome market?
The human microbiome market products includes probiotics, prebiotics, diagnostic tests, drugs, and other products. The othe products includes foods, medical foods, synbiotics, and next-generation therapeutics, among others.
What is the COVID-19 impact on the human microbiome market?
The COVID-19 has adversely impacted companys businesses, including their preclinical studies and clinical trials of microbiome-based therapeutics and diagnostics products .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 23)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED FOR THE HUMAN MICROBIOME MARKET
1.3.2 MARKETS COVERED FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET
1.3.3 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME RESEARCH SPENDING MARKET)
1.3.4 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME DIAGNOSTIC APPLICATIONS MARKETS)
1.3.5 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME THERAPEUTIC APPLICATION MARKETS)
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 28)
2.1 RESEARCH APPROACH
2.1.1 SECONDARY DATA
2.1.2 PRIMARY SOURCES
FIGURE 1 BREAKDOWN OF PRIMARIES: HUMAN MICROBIOME MARKET
2.2 MARKET DATA ESTIMATION AND TRIANGULATION
FIGURE 2 DATA TRIANGULATION METHODOLOGY
2.2.1 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION APPROACH: R&D SPENDING ANALYSIS-BASED ESTIMATION (FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET)
FIGURE 4 HUMAN MICROBIOME RESEARCH SPENDING MARKET SIZE (USD MILLION): FINAL MARKET SIZE
2.2.2 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 5 FINAL CAGR PROJECTIONS (2020−2025)
2.2.3 POTENTIAL MARKET SIZE CALCULATION FOR HUMAN MICROBIOME MARKET
FIGURE 6 HUMAN MICROBIOME MARKET SIZE BASED ON EPIDEMIOLOGY APPROACH
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
2.3 RESEARCH ASSUMPTIONS
3 EXECUTIVE SUMMARY (Page No. - 35)
FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2025 VS. 2028 (USD MILLION)
FIGURE 9 HUMAN MICROBIOME MARKET SHARE, BY APPLICATION, 2024
FIGURE 10 HUMAN MICROBIOME MARKET, BY DISEASE, 2025 VS. 2028 (USD MILLION)
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE HUMAN MICROBIOME MARKET
4 PREMIUM INSIGHTS (Page No. - 38)
4.1 HUMAN MICROBIOME: MARKET OVERVIEW
FIGURE 12 INCREASING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE THE GROWTH OF THIS MARKET
4.2 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY (2020 VS. 2025)
FIGURE 13 GENOMIC TECHNOLOGIES DOMINATED THE HUMAN MICROBIOME RESEARCH SPENDING MARKET IN 2020
4.3 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT & APPLICATION (2024)
4.4 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY (20202025)
FIGURE 14 CHINA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 42)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 MARKET DRIVERS
5.2.1.1 Increasing focus on human microbiome therapeutics development
5.2.1.2 Human microbiome as a validated target for drug development
5.2.1.3 Development of human microbiome-based tests for early disease detection & diagnosis
5.2.2 MARKET OPPORTUNITIES
5.2.2.1 Increasing collaborations between public-private organizations
5.2.3 MARKET CHALLENGES
5.2.3.1 Government regulations
5.2.3.2 Lack of expertise and inadequate research
5.2.4 MARKET RESTRAINTS
5.2.4.1 Barriers in proving the causal link between dysbiosis and diseases
5.3 IMPACT OF THE COVID-19 ON THE MARKET
5.4 TECHNOLOGY ANALYSIS
5.5 REGULATORY ANALYSIS
5.5.1 FOR HUMAN MICROBIOME-BASED DRUGS CATEGORY
5.5.2 FOR HUMAN MICROBIOME-BASED FOODS CATEGORY
5.6 PATENT ANALYSIS
6 HUMAN MICROBIOME MARKET, BY PRODUCT (Page No. - 53)
6.1 INTRODUCTION
TABLE 1 HUMAN MICROBIOME MARKET, BY PRODUCT, 20192028 (USD MILLION)
6.2 DRUGS
6.2.1 INCREASING NUMBER OF MICROBIOME-BASED DRUGS IN THE PIPELINE IS A KEY FACTOR DRIVING MARKET GROWTH
TABLE 2 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 20222028 (USD MILLION)
TABLE 3 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY 20222028 (USD MILLION)
6.3 DIAGNOSTIC TESTS
6.3.1 GROWING CONSUMER AWARENESS ABOUT MICROBIOME-BASED TESTS TO DRIVE MARKET GROWTH
TABLE 4 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 20192028 (USD MILLION)
TABLE 5 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY 20192028 (USD MILLION)
6.4 PROBIOTICS
6.4.1 ONGOING RESEARCH ON PROBIOTICS IS PROMOTING ITS CREDIBILITY IN HEALTH CLAIMS AND SAFETY, THUS DRIVING MARKET GROWTH
TABLE 6 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 20232028 (USD MILLION)
TABLE 7 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 20192028 (USD MILLION)
6.5 PREBIOTICS
6.5.1 DEVELOPMENT OF TARGETED PREBIOTICS IN ENHANCING GUT MICROBIOTA IS THE KEY GROWTH DRIVER FOR THIS SEGMENT
TABLE 8 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 20232028 (USD MILLION)
TABLE 9 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023- 2028 (USD MILLION)
6.6 OTHER PRODUCTS
TABLE 10 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 20232028 (USD MILLION)
TABLE 11 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2028 (USD MILLION)
7 HUMAN MICROBIOME MARKET, BY DISEASE (Page No. - 61)
7.1 INTRODUCTION
TABLE 12 HUMAN MICROBIOME MARKET, BY DISEASE, 20222028 (USD MILLION)
7.2 INFECTIOUS DISEASES
7.2.1 INCREASING NUMBER OF CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO DRIVE MARKET GROWTH
TABLE 13 DEVELOPMENT OF MICROBIOME-BASED DRUGS FOR INFECTIOUS DISEASES
TABLE 14 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 20222027 (USD MILLION)
TABLE 15 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 20222028 (USD MILLION)
7.3 GASTROINTESTINAL DISEASES
7.3.1 INCREASING NUMBER OF CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO DRIVE MARKET GROWTH
TABLE 16 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 20222028 (USD MILLION)
TABLE 17 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 20222028 (USD MILLION)
7.4 ENDOCRINE & METABOLIC DISORDERS
7.4.1 THE DEVELOPMENT OF MICROBIOME MODULATORS FOR THE TREATMENT OF METABOLIC DISORDERS DRIVES MARKET GROWTH
TABLE 18 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2022-2028 (USD MILLION)
TABLE 19 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 20222028 (USD MILLION)
7.5 CANCER
7.5.1 MICROBIOME-BASED PRODUCTS HAVE DEMONSTRATED EFFICACY IN THE TREATMENT OF PELVIC AND COLON CANCER
TABLE 20 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 20222028 (USD MILLION)
TABLE 21 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 20222028 (USD MILLION)
7.6 OTHER DISEASES
TABLE 22 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 20222028 (USD MILLION)
TABLE 23 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 20222028 (USD MILLION)
8 HUMAN MICROBIOME MARKET, BY APPLICATION (Page No. - 69)
8.1 INTRODUCTION
TABLE 24 HUMAN MICROBIOME MARKET, BY APPLICATION, 20192028 (USD MILLION)
8.2 THERAPEUTIC APPLICATIONS
8.2.1 AVAILABILITY OF FUNDING FOR THE DEVELOPMENT OF MICROBIOME-BASED THERAPEUTIC PRODUCTS TO DRIVE MARKET GROWTH
TABLE 25 HUMAN MICROBIOME MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 20192028 (USD MILLION)
TABLE 26 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 20192028 (USD MILLION)
8.3 DIAGNOSTIC APPLICATIONS
8.3.1 INCREASING FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET GROWTH
TABLE 27 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 20192028 (USD MILLION)
TABLE 28 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 20192028 (USD MILLION)
9 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY (Page No. - 73)
9.1 INTRODUCTION
TABLE 29 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
9.2 GENOMICS
TABLE 30 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 20182025 (USD MILLION)
TABLE 31 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY REGION, 20182025 (USD MILLION)
TABLE 32 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 33 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 34 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 20182025 (USD MILLION)
9.2.1 SEQUENCING
TABLE 35 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY REGION, 20182025 (USD MILLION)
TABLE 36 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 20182025 (USD MILLION)
TABLE 37 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 20182025 (USD MILLION)
TABLE 38 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 20182025 (USD MILLION)
TABLE 39 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY METHOD, 20182025 (USD MILLION)
9.2.1.1 16S rRNA Sequencing Method
9.2.1.1.1 This method is a cost-effective technique for the identification of bacterial strains
TABLE 40 16S RRNA SEQUENCING METHOD, BY REGION, 20182025 (USD MILLION)
TABLE 41 NORTH AMERICA: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 20182025 (USD MILLION)
TABLE 42 EUROPE: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 20182025 (USD MILLION)
TABLE 43 ASIA PACIFIC: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 20182025 (USD MILLION)
9.2.1.2 Whole-Genome Sequencing(WGS)Method
9.2.1.2.1 WGS helps generate accurate reference genomes for microbial identification
TABLE 44 WGS METHOD, BY REGION, 20182025 (USD MILLION)
TABLE 45 NORTH AMERICA: WGS METHOD, BY COUNTRY, 20182025 (USD MILLION)
TABLE 46 EUROPE: WGS METHOD, BY COUNTRY, 20182025 (USD MILLION)
TABLE 47 ASIA PACIFIC: WGS METHOD, BY COUNTRY, 20182025 (USD MILLION)
9.2.1.3 Other Sequencing Methods
TABLE 48 OTHER SEQUENCING METHODS, BY REGION, 20182025 (USD MILLION)
TABLE 49 NORTH AMERICA: OTHER SEQUENCING METHODS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 50 EUROPE: OTHER SEQUENCING METHODS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 51 ASIA PACIFIC: OTHER SEQUENCING METHODS BY COUNTRY, 20182025 (USD MILLION)
9.2.2 OTHER GENOMIC TECHNOLOGIES
TABLE 52 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY REGION, 20182025 (USD MILLION)
TABLE 53 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 20182025 (USD MILLION)
TABLE 54 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 20182025 (USD MILLION)
TABLE 55 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 20182025 (USD MILLION)
9.3 PROTEOMICS
9.3.1 TECHNOLOGICAL ADVANCEMENTS IN PROTEOMIC TECHNOLOGIES TO DRIVE MARKET GROWTH
TABLE 56 PROTEOMICS, BY REGION, 20182025 (USD MILLION)
TABLE 57 NORTH AMERICA: PROTEOMICS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 58 EUROPE: PROTEOMICS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 59 ASIA PACIFIC: PROTEOMICS, BY COUNTRY, 20182025 (USD MILLION)
9.4 METABOLOMICS
9.4.1 ADVANTAGES OF METABOLOMICS OVER GENOMICS AND PROTEOMICS IN MICROBIOME RESEARCH TO DRIVE MARKET GROWTH
TABLE 60 METABOLOMICS, BY REGION, 20182025 (USD MILLION)
TABLE 61 NORTH AMERICA: METABOLOMICS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 62 EUROPE: METABOLOMICS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 63 ASIA PACIFIC: METABOLOMICS, BY COUNTRY, 20182025 (USD MILLION)
10 HUMAN MICROBIOME MARKET, BY REGION (Page No. - 87)
10.1 INTRODUCTION
TABLE 64 HUMAN MICROBIOME MARKET, BY REGION, 20192028 (USD MILLION)
TABLE 65 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY REGION, 20182025 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 16 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
TABLE 66 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 20192028 (USD MILLION)
TABLE 67 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 20192028 (USD MILLION)
TABLE 68 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2022-2028 (USD MILLION)
TABLE 69 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 20192025 (USD MILLION)
TABLE 70 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 71 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 72 NORTH AMERICA: GENOMICS MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 73 NORTH AMERICA: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
10.2.1 US
10.2.1.1 Increasing investments by NIH in support of microbiome research is driving the market growth in the US
TABLE 74 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 20192028 (USD MILLION)
TABLE 75 US: HUMAN MICROBIOME MARKET, BY APPLICATION, 20192028 (USD MILLION)
TABLE 76 US: HUMAN MICROBIOME MARKET, BY DISEASE, 20222028 (USD MILLION)
TABLE 77 US: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 78 US: GENOMICS MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 79 US: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing government support and funds support market growth for microbiome research in Canada
TABLE 80 INDICATIVE LIST OF PROJECTS ON THE HUMAN MICROBIOME IN 2018
TABLE 81 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 20192028 (USD MILLION)
TABLE 82 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 20192028 (USD MILLION)
TABLE 83 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2022-2028 (USD MILLION)
TABLE 84 CANADA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 85 CANADA: GENOMICS MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 86 CANADA: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
10.3 EUROPE
TABLE 87 EU MICROBIOME PROJECT
TABLE 88 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 20192028 (USD MILLION)
TABLE 89 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 20192028 (USD MILLION)
TABLE 90 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 20222028 (USD MILLION)
TABLE 91 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 92 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 93 EUROPE: GENOMICS MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 94 EUROPE: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Extended applications of microbiome research to therapeutic areas to boost the adoption of microbiome-based products in Germany
TABLE 95 GERMANY: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 96 GERMANY: GENOMICS MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 97 GERMANY: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
10.3.2 UK
10.3.2.1 Increasing focus on the development of microbiome-based products in the UK to drive market growth
TABLE 98 UK: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 99 UK: GENOMICS MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 100 UK: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing funding to boost the development of microbiome-based products in Europe
TABLE 101 FRANCE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 102 FRANCE: GENOMICS MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 103 FRANCE: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
10.3.4 ROE
TABLE 104 ROE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 105 ROE: GENOMICS MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 106 ROE: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 17 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT
TABLE 107 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 20192028 (USD MILLION)
TABLE 108 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 20192028 (USD MILLION)
TABLE 109 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 20222028 (USD MILLION)
TABLE 110 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 111 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 112 ASIA PACIFIC: GENOMICS MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 113 ASIA PACIFIC: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
10.4.1 CHINA
10.4.1.1 A large number of human microbiome research studies are conducted in China, thus driving market growth
TABLE 114 INDICATIVE LIST OF HUMAN MICROBIOME RESEARCH STUDIES CONDUCTED IN CHINA
TABLE 115 CHINA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 116 CHINA: GENOMICS TECHNOLOGY MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 117 CHINA: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Increasing focus on funding for microbiome-based products to drive market growth
TABLE 118 JAPAN: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 119 JAPAN: GENOMICS MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 120 JAPAN: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Government funding to drive the development of microbiome-based products in India
TABLE 121 INDIA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 122 INDIA: GENOMICS MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 123 INDIA: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
10.4.4 ROAPAC
TABLE 124 ROAPAC: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 125 ROAPAC: GENOMICS MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 126 ROAPAC: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
10.5 REST OF THE WORLD (ROW)
TABLE 127 ROW: HUMAN MICROBIOME MARKET, BY PRODUCT, 20192028 (USD MILLION)
TABLE 128 ROW: HUMAN MICROBIOME MARKET, BY APPLICATION, 20192028 (USD MILLION)
TABLE 129 ROW: HUMAN MICROBIOME MARKET, BY DISEASE, 2022-2028 (USD MILLION)
TABLE 130 ROW: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 131 ROW: GENOMICS MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 132 ROW: SEQUENCING MARKET, BY METHOD, 20182025 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 121)
11.1 OVERVIEW
11.2 COMPANY PRODUCT FOOTPRINT
FIGURE 18 PRODUCT PORTFOLIO ANALYSIS: HUMAN MICROBIOME MARKET
11.3 COMPETITIVE SCENARIO
TABLE 133 HUMAN MICROBIOME MARKET: DEALS, JANUARY 2020JANUARY 2021
12 COMPANY PROFILES (Page No. - 125)
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 ENTEROME
12.2 SERES THERAPEUTICS
FIGURE 19 SERES THERAPEUTICS: COMPANY SNAPSHOT (2019)
12.3 4D PHARMA PLC
FIGURE 20 4D PHARMA PLC: COMPANY SNAPSHOT (2019)
12.4 EVELO BIOSCIENCES, INC.
FIGURE 21 EVEL0 BIOSCIENCES, INC.: COMPANY SNAPSHOT (2019)
12.5 OPTIBIOTIX HEALTH PLC
FIGURE 22 OPTIBIOTIX HEALTH PLC: COMPANY SNAPSHOT (2019)
12.6 SYNLOGIC
FIGURE 23 SYNLOGIC: COMPANY SNAPSHOT (2019)
12.7 SECOND GENOME
12.8 VEDANTA BIOSCIENCES, INC.
12.9 FERRING PHARMACEUTICALS
12.10 VITHERA PHARMACEUTICALS, INC.
12.11 BIOMX
FIGURE 24 BIOMX: COMPANY SNAPSHOT (2019)
12.12 DUPOINT
FIGURE 25 DU PONT: COMPANY SNAPSHOT (2019)
12.13 KALEIDO
FIGURE 26 KALEIDO: COMPANY SNAPSHOT (2019)
12.14 YSOPIA BIOSCIENCE
12.15 FLIGHTPATH
12.16 FINCH THERAPEUTICS GROUP, INC
12.17 QUANTBIOME, INC. (DBA THRYVE)
12.18 VIOME, INC.
12.19 DAYTWO INC
12.20 BIOHM
12.21 ATLAS BIOMED GROUP LIMITED.
12.22 BIONE
12.23 LUXIA SCIENTIFIC
12.24 SUN GENOMICS
12.25 METABIOMICS
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 170)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global human microbiome market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The human microbiome market's size was estimated through various secondary research approaches and triangulated with inputs from primary research.
Secondary data
The secondary sources referred to for this research study include publications from government sources such as the World Health Organization (WHO), Human Microbiome Project (HMP), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), Food and Drug Administration (FDA), ClinicalTrials.gov, Expert Interviews, and MarketsandMarkets Analysis); business magazines and research journals; press releases; and trade, business, and professional associations.
Secondary data was collected and analyzed to arrive at the global human microbiome market's overall size, which was validated through primary research.
Primary sources
In the primary research process, various sources from the supply sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, technology & innovation directors, personnel from research organizations, physicians, academic institutes, and related key executives from various key companies and organizations operating in the human microbiome market.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
In this report, the global potential market size for the human microbiome was calculated using the epidemiology approach.
- Key indications were identified for which microbiome therapy clinical trials are underway
- For respective disease categories, estimating the potential market for microbiome-based drugs from existing non-microbiome-based drugs market Microbiome therapeutics are likely to be adopted by a set of patients who show side-effects for existing therapies. Therefore, the percentage of the patient population showing some side-effects with existing therapies was identified. This percentage was then applied to the total therapy market to derive the human microbiome's total addressable market.
- To calculate the total market for microbiome therapy, the penetration rate for microbiome therapies was applied to the total addressable market
- Primary experts then validated this approach.
Individual shares of each product, disease, region, and application were arrived at based on parameters such as product pipeline, clinical trials progress, target indications, funding scenario, and research intensity in the microbiome.
Data Triangulation
After arriving at the overall market sizeusing the market size estimation processes explained abovethe market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides of the human microbiome market.
Report Objectives
- To define, describe, segment, and forecast the human microbiome market based on product, application, disease, and region
- To define, describe, segment, and forecast the human microbiome research spending market based on technology
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets1 and subsegments with respect to individual growth trends, future prospects, and contributions to the overall human microbiome market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments concerning four main regions (along with countries), namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (South America, Latin America, and the Middle East & Africa)
- To strategically analyze the market structure and profile the key players of the global human microbiome market and comprehensively analyze their core competencies2
- To track and analyze competitive developments such as acquisitions; partnerships, agreements, & collaborations; and product launches in the human microbiome market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs.
The following customization option is available for the report:
Additional Company Profiles
- Company profiles for five additional companies.
Get in-depth analysis of the COVID-19 impact on the Human Microbiome Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Human Microbiome Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Human Microbiome Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Human Microbiome Market